Barclays raised the firm’s price target on Blueprint Medicines to $58 from $46 and keeps an Equal Weight rating on the shares following the “strong beat” in Q3.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BPMC: